Pharmaphorum
Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
Pharmaphorum
Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
Pharmaphorum
Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.